Unmet Needs in Advanced or Metastatic TRK Fusion-Positive Thyroid Cancer
Marie E. Cabanillas, MD, discusses current unmet needs in advanced or metastatic TRK fusion-positive thyroid cancer.
Marie E. Cabanillas, MD, an oncologic endocrinologist at the University of Texas MD Anderson Cancer Center, discusses current unmet needs in advanced or metastatic TRK fusion-positive thyroid cancer.
According to Cabanillas, more options for RET, ALK, and BRAF mutations exist. TRK mutations are another rare fusion requiring an inhibitor. Additionally, there are limitations on the 2 currently approved therapies, sorafenib (Nexavar) and lenvatinib (Lenvima).
For some patients, these therapies are too dangerous, according to Cabanillas. For patients who have a predisposition for bleeding, especially bleeding from the tumor VEGF inhibitors may be unsafe as they may increase bleeding risk. There is a need for more tolerable therapies for this patient population.
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
Dual Immunotherapy Clinically Active in Anaplastic Thyroid Cancer
December 23rd 2024A phase 2 trial found that dual immune checkpoint inhibition with nivolumab and ipilimumab shows promise in anaplastic thyroid cancer, but limited effectiveness in radioiodine refractory differentiated thyroid carcinoma.
Read More
Post Hoc and Real-World Analyses Explore Benefit of Lenvatinib in DTC
December 5th 2024During a Case-Based Roundtable® event, Lori J. Wirth, discussed recent analyses that have developed a better understanding of the outcomes with lenvatinib in differentiated thyroid cancer in the second article of a 2-part series.
Read More
